New method to evaluate pancreatic prognosis

The present invention relates to the prediction of the survival time of a patient suffering of a pancreatic cancer. In this study, the inventors aimed to determine whether PDAC could be stratified on the basis of their GT gene expression profiles involved in the biosynthesis of glycoconjugates. By using bioinformatic analysis of RNA-seq data focused on 169 GT genes from patient-derived xenografts (PDX), they have identified a combination of 19 GT, which was able to discriminate 3 clusters of PDAC associated with specific molecular profiles and clinical features of patients. These GT genes were validated on public databases as a prognostic glyco-signature, which could allow best patient care in the future and also highlight new potential targets for diagnosis and prognosis of PDAC. Thus, the invention relates to a method for predicting the survival time of a patient suffering from a pancreatic cancer comprising i) determining in a sample obtained from the patient the expression level of at least one gene selected in the group consisting in GALNT9, A4GNT, B3GALT5, B3GNT6, C1GALT1, FUT2, FUT3, FUT4, FUT6, GALNT4, GALNT6, GALNT12, GCNT1, GYG2, LFNG, MGAT5, ST6GALNAC1, ST8SIA3 and XYLT.

Keywords: Pancreatic Cancer, RNA signatiure, RNA-Seq, Glycoprotein metabolism signature, Prognosis
Patent Application number: European Procedure (Patents) (EPA) - 29 Mars 2021 - 21 305 391.1
EBioMedicine 2021 Sep Abd-El-Halim et al. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis doi: 10.1016/j.ebiom.2021.103541. Epub 2021 Aug 20.



    Business Developper
    Inserm Transfert
    Business Developer
    Patent filling date: 29-03-2021
    Rare disease: No
    Second indication: No

    You might also be interested in